Glycoprotein 100 peptide–HLA-A*02:01 complex (null)

The glycoprotein 100 peptide–HLA-A*02:01 complex is comprised of a peptide derived from the gp100 (PMEL) protein, an antigen highly expressed in melanocytes and melanoma cells, bound to the MHC class I molecule HLA-A*02:01. This peptide–MHC complex is displayed on the surface of cells and is recognized by cytotoxic T lymphocytes. It serves as a target for immunotherapies, including tebentafusp, which uses an affinity-enhanced TCR domain to bind this complex and redirect T cells to mediate tumor cell lysis. Targeting this complex allows for selective killing of melanoma cells in patients expressing HLA-A*02:01[3][2].

Other names

gp100-HLA-A*02:01 complexPMEL-HLA-A*02:01 complexgp100 peptide–MHC class I complex (HLA-A2)

Enables T-cell mediated cytolysis: Drugs like tebentafusp act as T cell engagers, binding to the gp100 peptide–HLA-A*02:01 complex on cancer cells, recruiting and activating CD3+ T cells to kill the target cell[3].